We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.
- Authors
Bergh, J; Wiklund, T; Erikstein, B; Lidbrink, E; Lindman, H; Malmström, P; Kellokumpu-Lehtinen, P; Bengtsson, N O; Söderlund, G; Anker, G; Wist, E; Ottosson, S; Salminen, E; Ljungman, P; Holte, H; Nilsson, J; Blomqvist, C; Wilking, N
- Abstract
Chemotherapy drug distribution varies greatly among individual patients. Therefore, we developed an individualised fluorouracil, epirubicin, cyclophosphamide (FEC) regimen to improve outcomes in patients with high-risk early breast cancer. We then did a randomised trial to compare this individually tailored FEC regimen with conventional adjuvant chemotherapy followed by consolidation with high-dose chemotherapy with stem-cell support.
- Publication
Lancet (London, England), 2000, Vol 356, Issue 9239, p1384
- ISSN
0140-6736
- Publication type
Journal Article
- DOI
10.1016/s0140-6736(00)02841-5